The tender offer removes warrant overhang at a modest cash cost, signaling management's focus on capital structure clarity post-Kira merger. Monitor tender results after November 6 expiration — high participation would meaningfully reduce future dilution risk. The absence of a trading market for the warrants (per the amendment) may pressure holders to tender.
Price Chart
Executive Summary
Jasper Therapeutics is amending its issuer tender offer to repurchase any and all of its 12,345,707 outstanding warrants (JSPRW) at $0.324 per warrant in cash, funded from cash on hand. The offer expires November 6, 2026, and is designed to reduce potential dilution from warrant exercise, providing greater capital structure certainty. The amendment removes certain forward-looking statement references and clarifies there is no trading market for the warrants.
Key Financial Metrics
Key Facts
- Jasper offers to buy any and all of its 12,345,707 outstanding warrants at $0.324 per warrant in cash.
- Warrants have an exercise price of $2.92 per share and expire March 18, 2030.
- Maximum cost at 100% participation is approximately $4.0 million, funded from cash on hand.
- Offer period runs from October 7, 2026 to November 6, 2026, subject to extension.
- Board approved the offer but makes no recommendation to warrant holders.
- Amendment No. 1 removes references to Section 27A of Securities Act and Section 21E of Exchange Act, and states no trading market exists for the warrants.
- Velan Capital Management and affiliates hold 9.9% of common stock; MCN Holdco holds 8.1%.
- Three directors (Wiggans, Shizuru, Lucas) hold a total of 102,000 warrants and may tender them.
Financial Impact
Up to $4.0 million cash outflow to retire all outstanding warrants, reducing potential dilution by up to 12.3 million shares (37% of current 33.3M shares outstanding).
Risk Factors
- Low tender participation would leave dilution risk largely intact.
- Warrants may expire worthless if common stock stays below $2.92 exercise price.
- Nasdaq delisting risk if continued listing standards not met.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-I/A Filing (Primary) | 0001213900-26-112090 |
| Document: ea0309476-sctoia1_jasper.htm | 0001213900-26-112090 |
| Document: 0001213900-26-112090-index-headers.html | 0001213900-26-112090 |
| Document: 0001213900-26-112090-index.html | 0001213900-26-112090 |
| Document: 0001213900-26-112090.txt | 0001213900-26-112090 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5098 (−0.04%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5098 (+1.98%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5098 (−4.19%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5098 (+4.17%) |
Oct 14, 2026 11d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5098 (+4.19%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5098 (−10.51%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5098 (−10.51%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5098 (+16.30%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5098 (−35.48%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5098 (−19.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers